#GSK reported good #clinicaltrialresults with two of its #lungcancer therapies – #Jideytro and #risvutatugrezetecan (ris-rez) – at the ongoing #WCLC congress in #Seoul, South Korea.
@pharmaphorum.bsky.socialExplore
@pharmaphorum.bsky.social
@pharmaphorum.bsky.social#GSK reported good #clinicaltrialresults with two of its #lungcancer therapies – #Jideytro and #risvutatugrezetecan (ris-rez) – at the ongoing #WCLC congress in #Seoul, South Korea.